Bristol Myers Squibb vs Gilead (BMY vs GILD)

Bristol Myers Squibb (BMY) vs Gilead (GILD) in plain English: P/E, growth, margins, debt and dividend side by side, key differences and which fits each investor profile.

Bristol Myers Squibb (BMY) and Gilead (GILD) compete in healthcare and pharma. Here are Bristol Myers Squibb and Gilead side by side with their real figures as of November 4, 2026: what sets them apart, which fits each kind of investor and the most common questions, without telling you whether to buy Bristol Myers Squibb or Gilead.

Bristol Myers Squibb vs Gilead: the figures

Bristol Myers Squibb and Gilead figures from Yahoo Finance, the same source the Fintols analysis uses, retrieved on November 4, 2026; N/A means that Bristol Myers Squibb or Gilead figure is not available, and we never estimate it.

3 key differences between Bristol Myers Squibb and Gilead

1. Profitability: for every 100 of sales, Bristol Myers Squibb keeps 18.5 as net profit and Gilead keeps -12.5.
2. Dividend: Bristol Myers Squibb yields 4.08% at today's price and Gilead yields 1.96%.
3. Volatility: Gilead stock moves more (beta 0.37) than Bristol Myers Squibb (beta 0.19); the higher the beta, the more it amplifies market swings.

Bristol Myers Squibb or Gilead: which fits your profile

• If you want growth: Bristol Myers Squibb is growing faster today, so it fits better with investors who put business growth first, usually accepting a higher P/E and a bumpier ride.
• If you want income (dividends): Bristol Myers Squibb pays the higher dividend relative to its price.
• If you prefer caution: Gilead has less debt relative to its profit, which usually gives more room in a bad year.

Neither Bristol Myers Squibb nor Gilead wins on everything, and owning both is also an option: spreading money across several companies or an index fund reduces what rides on each one.

How Bristol Myers Squibb and Gilead make money

Bristol Myers Squibb (BMY)

Bristol Myers Squibb sells prescription drugs in a single segment. Its biggest products are Eliquis, a blood thinner marketed with Pfizer, and Opdivo, a cancer immunotherapy, along with Revlimid, Pomalyst, Breyanzi, Camzyos and the schizophrenia drug Cobenfy. The United States generates most of its revenue. Full Bristol Myers Squibb analysis.

Gilead (GILD)

Gilead Sciences is a biotech whose largest revenue source is HIV treatment and prevention, led by Biktarvy, alongside Descovy and Yeztugo. It also sells cancer drugs, including Trodelvy and Kite's cell therapies Yescarta and Tecartus, liver disease treatments such as Epclusa and Livdelzi, and the antiviral Veklury. Full Gilead analysis.

Frequently asked questions: Bristol Myers Squibb vs Gilead

Is Bristol Myers Squibb or Gilead the better stock?

Choosing between Bristol Myers Squibb and Gilead depends on what you are looking for. Bristol Myers Squibb is growing faster right now. Fintols does not tell you whether to buy Bristol Myers Squibb or Gilead: it shows you the differences so you can decide.

Which pays a higher dividend, Bristol Myers Squibb or Gilead?

As of November 4, 2026, Bristol Myers Squibb yields 4.08% and Gilead yields 1.96%. Also check how much of their profit Bristol Myers Squibb and Gilead pay out: if it is more than they earn, it cannot last.

Can I own both Bristol Myers Squibb and Gilead?

Yes. Many people spread their money across several companies, such as Bristol Myers Squibb and Gilead, or use index funds so they do not depend on just one. If you are starting out, decide how much you want to invest and for how long before buying Bristol Myers Squibb or Gilead.

More comparisons with Bristol Myers Squibb or Gilead

• Bristol Myers Squibb vs CVS Health
• Bristol Myers Squibb vs Danaher
• Bristol Myers Squibb vs Eli Lilly
• CVS Health vs Gilead

More companies like Bristol Myers Squibb and Gilead: healthcare and pharma stocks. Educational content about Bristol Myers Squibb and Gilead, not investment advice.